Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, adult
Stage/Subtype:  adult nasal type extranodal NK/T-cell lymphoma, stage I mantle cell lymphoma, stage II mantle cell lymphoma, stage III mantle cell lymphoma, stage IV mantle cell lymphoma, recurrent mantle cell lymphoma
Trial Type:  Treatment
Trial Status:  Active
Trial Phase:  Phase III
Results 1-25 of 25 for your search:
Start Over
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459685, DSHNHL-2004-2, EU-205110, EUDRACT-2005-00521738, DSHNHL-FLYER-6664, NCT00278421
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459796, DSHNHL-2004-3, EUDRACT-2005-005218-19, EU-205111, NCT00278408
Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Phase: Phase III
Type: Treatment
Status: Active
Age: 61 to 80
Sponsor: Other
Protocol IDs: DSHNHL 2006-1B / ACT-2, BMBF GFVT 01014715, NCT00725231
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NHL 7-2008, NCT00877214
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20120673, NCT01237639
Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCL2005-01, NCT01449344
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation
Phase: Phase III
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: 2081-076, NCT01530581
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: BMTCTN1101, 2U10HL069294-11, NCT01597778
Trial of GemOx±R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: JSPH-001, NCT01670370
Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CSWOG0002, NCT01788137
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL R2 Elderly, NCT01865110
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HD2002, NCT01933711
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-NHL-008, NCT01996865
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NKT-SYSUCC-2013, NCT02085655
Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 69
Sponsor: Other
Protocol IDs: SYSUCC-NK-308, NCT02359162
Start Over